Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 4
Submit an article Journal homepage
944
Views
15
CrossRef citations to date
0
Altmetric
Drug Profile

Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer

John A Carter Pharmerit North America LLC, 4350 East West Highway, Suite 430, Bethesda, MD 20814, USA
&
Marc F Botteman Pharmerit North America LLC, 4350 East West Highway, Suite 430, Bethesda, MD 20814, USA. [email protected]
Pages 425-437 | Published online: 09 Jan 2014

References

  • Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev. 19(8), 1893–1907 (2010).
  • Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27(3), 165–176 (2001).
  • Costa L, Lipton A, Coleman RE. Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther. 3(3), 143–153 (2006).
  • Barlev A, Song X, Ivanov B, Setty V, Chung K. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J. Manag. Care Pharm. 16(9), 693–702 (2010).
  • Sathiakumar N, Delzell E, Morrisey MA et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006. Prostate Cancer Prostatic. Dis. 14(2), 177–183 (2011).
  • Bouganim N, Clemons MJ. Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block? Future Oncol. 7(3), 381–383 (2011).
  • Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur. Urol. 46(6), 731–739 (2004).
  • Coleman RE, Seaman JJ. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Semin. Oncol. 28(2 Suppl. 6), S11–S16 (2001).
  • Coleman RE. Bisphosphonates: clinical experience. Oncologist 9(Suppl. 4), S14–S27 (2004).
  • Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther. 4(2), 92–100 (2007).
  • Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94(19), 1458–1468 (2002).
  • Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst. 96(11), 879–882 (2004).
  • Polascik TJ, Given RW, Metzger C et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 66(5), 1054–1059 (2005).
  • US Food and Drug Administration. Xgeva BLA 125320/7 Approval Letter. 2010
  • European Medicines Agency. Xgeva. In: EPAR Summary for the Public. European Medicines Agency, London, UK (2012).
  • Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768), 813–822 (2011).
  • Aapro MS. Denosumab for bone metastases from breast cancer: a new therapy option? J. Clin. Oncol. 29(14), e419–e420 (2011).
  • Aragon-Ching JB. Unravelling the role of denosumab in prostate cancer. Lancet 377(9768), 785–786 (2011).
  • West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J. Clin. Oncol. 29(9), 1095–1098 (2011).
  • Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Actas Urol. Esp. 35(10), 565–579 (2011).
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer, Version 1.2012. In: National Comprehensive Cancer Network; 2012. National Comprehensive Cancer Network, PA, USA, 1–68 (2012).
  • Carter JA, Joshi A, Kaura S, Botteman MF. Cost–effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and The Netherlands. J. Med. Econ. 14(3), 288–298 (2011).
  • Ford J, Cummins E, Sharma P et al. Systematic review of the clinical effectiveness and cost–effectiveness and economic evaluation of denosumab for the treatment of bone metastases from solid tumors. In: Aberdeen HTA Group, Institure of Applied Sciences. University of Aberdeen, UK (2011).
  • Reed SD, Radeva JI, Glendenning GA, Saad F, Schulman KA. Cost–effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J. Urol. 171(4), 1537–1542 (2004).
  • Stopeck A, Rader M, Henry D et al. Cost–effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J. Med. Econ. doi:10.3111/13696998.2012.675380 (2012) (Epub ahead of print).
  • Xie J, Namjoshi M, Wu EQ et al. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J. Manag. Care Pharm. 17(8), 621–643 (2011).
  • Botteman M, Bargout V, El Ouagari K. Cost–effectiveness of zoledronic acid vs pamidronate in the management of hormone refractory prostate cancer (HRPC) patients with bone metastases [Abstract]. Presented at: American Society of Clinical Oncology Genitourinary Cancer Symposium. Atlanta, GA, USA, 2–6 June 2006.
  • Botteman M, Meijboom M, Kaura S, Durand-Zaleski I. Cost–effectiveness of zoledronic acid for the prevention of skeletal-related events in prostate cancer patients with bone metastases in France [Abstract]. Presented at: American Society of Clinical Oncology Genitourinary Cancer Symposium. Orlando, FL, USA, 29 May–2 June 2009.
  • Snedecor SJ, Carter JA, Kaura S, Botteman M. Cost–effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC). J. Clin. Oncol. (Suppl.), S29 (2011).
  • Yu A, Namjoshi J, Xie K et al. Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases [Abstract]. Presented at: American Society of Clinical Oncology Genitourinary Cancer Symposium. Chicago, IL, USA, 3–7 June 2011.
  • Carter J, Bains M, Chandiwana D, Kaura S, Botteman M. Cost–effectiveness of zoledronic acid versus pamidronate or no therapy for the treatment of bone metastases secondary to prostate cancer. Presented at: International Society for Pharmacoeconomics and Outcomes Research 14th Annual European Congress. Madrid, Spain, 5–8 November 2011.
  • Lothgren M, Bracco A, Lucius B et al. Cost–effectiveness of denosumab vs zoledronic acid (ZA) for the prevention of skeletal-related events (SRE) in patients with bone metastases from solid tumors in The Netherlands [Abstract]. Presented at: International Society for Pharmacoeconomics and Outcomes Research 14th Annual European Congress. Madrid, Spain, 5–8 November 2011.
  • El Ouagari K, Baladi J. Cost–effectiveness of treatment with zoledronic acid (Zometa®) in prostate cancer patients. Eur. J. Cancer 1(5), S256 (2003).
  • Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J. Clin. Oncol. 21(23), 4277–4284 (2003).
  • Weinfurt KP, Li Y, Castel LD et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann. Oncol. 16(4), 579–584 (2005).
  • Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 113(6), 1438–1445 (2008).
  • Rader M, Goessl C, Cong Z. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J. Manag. Care Pharm. 18(1), 74–75 (2012).
  • Sartor O. Denosumab in bone-metastatic prostate cancer: known effects on skeletal-related events but unknown effects on quality of life. Asian J. Androl. 13(4), 612–613 (2011).
  • McKean H, Miller RC, Jatoi A. Non-traumatic vertebral fractures in patients with locally advanced esophageal cancer: a previously unreported, unrecognized problem. Dis. Esophagus 20(2), 102–106 (2007).
  • Ross PD, Davis JW, Epstein RS, Wasnich RD. Pain and disability associated with new vertebral fractures and other spinal conditions. J. Clin. Epidemiol. 47(3), 231–239 (1994).
  • Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal-related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J. Urol. 184(1), 162–167 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.